tradingkey.logo
tradingkey.logo
Search

Genprex Inc

GNPX
Add to Watchlist
0.576USD
+0.042+7.80%
Close 07/02, 13:00ETQuotes delayed by 15 min
5.21MMarket Cap
LossP/E TTM

TradingKey Stock Score of Genprex Inc

Currency: USD Updated: 2026-07-02

Key Insights

Genprex Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 250 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is high.Over the past month, multiple analysts have rated it as , with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Genprex Inc's Score

Industry at a Glance

Industry Ranking
250 / 387
Overall Ranking
537 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Genprex Inc Highlights

StrengthsRisks
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Fairly Valued
The company’s latest PE is -0.11, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 65.88K shares, increasing 31.33% quarter-over-quarter.

Analyst Rating

Based on 0 analysts
--
Current Rating
7.500
Target Price
+3230.37%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Genprex Inc?

The TradingKey Stock Score provides a comprehensive assessment of Genprex Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Genprex Inc’s performance and outlook.

How do we generate the financial health score of Genprex Inc?

To generate the financial health score of Genprex Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Genprex Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Genprex Inc.

How do we generate the company valuation score of Genprex Inc?

To generate the company valuation score of Genprex Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Genprex Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Genprex Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Genprex Inc.

How do we generate the earnings forecast score of Genprex Inc?

To calculate the earnings forecast score of Genprex Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Genprex Inc’s future.

How do we generate the price momentum score of Genprex Inc?

When generating the price momentum score for Genprex Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Genprex Inc’s prices. A higher score indicates a more stable short-term price trend for Genprex Inc.

How do we generate the institutional confidence score of Genprex Inc?

To generate the institutional confidence score of Genprex Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Genprex Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Genprex Inc.

How do we generate the risk management score of Genprex Inc?

To assess the risk management score of Genprex Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Genprex Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Genprex Inc.